A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

Inclusion Criteria: * Adult patients 18 to 70 years of age * Diagnosis of mild to moderate pemphigus vulgaris within the past 12 months, requiring high dose corticosteroids Exclusion Criteria: * Female patients who are pregnant, breastfeeding, or lactating * Regularly scheduled plasma exchange (PE) or intravenous immunoglobulin (IVIG) treatment, or PE or IVIG treatment within 8 weeks prior to randomization * CellCept or other immunosuppressive therapy, except corticosteroids, exceeding 2 weeks total duration and within 8 weeks prior to randomization * Use of PV therapies other than those noted above, within 4 weeks prior to randomization * Use of topical corticosteroids within 2 weeks prior to randomization